Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

•  
• Uniform outline and structure of chapters allows readers to select and digest the information most relevant to them quickly and efficiently.
• Provides a definitive overview of the Alzheimer's disease drug development pipeline, with chapters devoted to the major aspects of drug discovery in sequence.
• Tackles a hugely topical subject matter, with almost 6 million Alzheimer's patients in the US alone and new treatments needed urgently.
• Aimed at the many individuals working in Alzheimer's disease drug development, the book helps readers understand their role and others' and how they intersect. This includes scientists involved in clinical trials, funding officials in private and public bodies, biotechnology and pharmaceutical companies, as well as students and clinicians working with Alzheimer's patients.
• Provides insight into how a drug such as the recently approved aducanumab is discovered, developed, approved, and marketed.